Skip to main content

Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

  • Investors Lab
  • Published:

Trials and error

Nature Biotechnology volume 23, page 1481 (2005)Cite this article

Biotech drugmaker stock prices are volatile not just at quarterly earnings time, but throughout the heavily regulated drug development process. Early signs of a drug's success or failure can dramatically change investment potential versus risk, so intelligent investing requires deep knowledge of the process. Because the United States is the world's richest drug market—and thus often the first market targeted by a company with a promising biotech product—it's worth focusing exclusively on US clinical trials to illustrate some important take-home messages for biotech investors.

The numbers

This is a preview of subscription content, access via your institution

Access options

Buy this article

  • Purchase on SpringerLink
  • Instant access to the full article PDF.

USD 39.95

Prices may be subject to local taxes which are calculated during checkout

Author information

Author notes

  1. Tom Jacobs is cofounder of Complete Growth Investor (http://www.completegrowth.com), a stock service for individual investors. He cannot give individual investment advice but welcomes your comments at tom@completegrowth.com.

Authors
  1. Tom Jacobs
    View author publications

    Search author on:PubMed Google Scholar

Rights and permissions

Reprints and permissions

About this article

Cite this article

Jacobs, T. Trials and error. Nat Biotechnol 23, 1481 (2005). https://doi.org/10.1038/nbt1205-1481

Download citation

  • Issue date:

  • DOI: https://doi.org/10.1038/nbt1205-1481

This article is cited by

Search

Advanced search

Quick links

Nature Briefing

Sign up for the Nature Briefing newsletter — what matters in science, free to your inbox daily.

Get the most important science stories of the day, free in your inbox. Sign up for Nature Briefing